"Hogan Lovells Advises MindMed on $259 Million Public Offering"

"Hogan Lovells advised Mind Medicine (MindMed) Inc., a biopharmaceutical company focused on brain health disorders, in its US$259 million public offering of 21,131,250 common shares at US$12.25 per share. The offering included the full exercise of underwriters' option to purchase additional shares. The law firm has a long-standing relationship with MindMed, having supported previous offerings in 2024."

Hogan Lovells advised Mind Medicine (MindMed) Inc. in its US$259 million public offering. The transaction involved the closing of an underwritten public offering of 21,131,250 common shares, including the exercise in full by the underwriters of their option to purchase an additional 2,756,250 common shares, at a public offering price of US$12.25 per share. All shares were offered by MindMed, generating gross proceeds of approximately US$259 million before deducting underwriting discounts, commissions, and offering expenses. The Hogan Lovells team was led by partner Steve Abrams (Capital Markets, Philadelphia), counsel Val Delp (Capital Markets, Philadelphia), senior associate Tyler Glass (Capital Markets, Philadelphia), and associates Spencer Leroux (Capital Markets, Northern Virginia) and Kayvon Paul (Capital Markets, Philadelphia). Additional support was provided by senior counsel Henry Kahn (M&A, Baltimore), partners Steven Kaufman (M&A, Washington, D.C.), Caitlin Piper (Tax, Pensions & Benefits, Washington, D.C.), and Lynn Mehler (Pharmaceuticals & Biotechnology, Washington, D.C.), and associate Katherine Kramer (Pharmaceuticals & Biotechnology, Washington, D.C.).

"Hogan Lovells Advises MindMed on $259 Million Public Offering"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads